NCT07109323View on ClinicalTrials.gov

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

March 2, 2028

Study Completion Date

March 2, 2030

Conditions
Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm DefinitionsCytogenetics Ultra High RiskPrimary RefractoryEarly ProgressionPlasma Cell LeukemiaNon Paraosseous Extramedullary InfiltrationR2-ISS-IV /MPSS-IV
Interventions
DRUG

BCMA CART

Bcma-cart was reinfused at a dose of 1.0-2.0 × 10 \^ 6 / kg on day +3 (± 1 day) after autologous hematopoietic stem cell reinfusion.

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
collaborator

Hebei Taihe Chunyu Biotechnology Co., Ltd

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER